Security Snapshot

Vera Therapeutics, Inc. - Class A Common Stock, par value $0.001 per share (VERA) Institutional Ownership

CUSIP: 92337R101

13F Institutional Holders and Ownership History from Q2 2021 to Q1 2026

Latest Period

Q1 2026

Institutions Reporting

227

Shares (Excl. Options)

72,234,409

Price

$40.23

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0.01%
Share change
-1,748,286
Value change
-$101,315,946
Number of holders
227
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
72,325,000
SEC-reported price per share
$39.15
Insider filing price
$39.15
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • VERA - Vera Therapeutics, Inc. - Class A Common Stock, par value $0.001 per share is tracked under CUSIP 92337R101.
  • 227 institutions reported positions in Q1 2026.
  • 9 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 214 to 227 between Q4 2025 and Q1 2026.
  • SEC-reported value moved from $3,747,901,676 to $2,918,504,853.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 227 institutions filings for Q1 2026.

Open SEC evidence

Security key

92337R101

Latest holder period

Q1 2026

13F holders

227

13D/G owners

9

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
9
Security
VERA
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Avoro Capital Advisors LLC 8.9% $134,640,000 5,610,000 Avoro Capital Advisors LLC 31 Dec 2024
PRICE T ROWE ASSOCIATES INC /MD/ 7.7% +33% $276,595,072 +$90,918,550 5,461,988 +49% T. Rowe Price Associates, Inc. 31 Dec 2025
Deep Track Capital, LP 5.5% $176,892,640 3,921,362 Deep Track Capital, LP 04 Mar 2026
VANGUARD GROUP INC 5% $180,805,107 3,570,401 The Vanguard Group 31 Dec 2025
Kynam Capital Management, LP 5.4% $83,444,698 3,426,887 Kynam Capital Management, LP 30 Jun 2025
Flynn James E 5.2% $75,299,151 3,348,117 Deerfield Mgmt, L.P. 06 Jun 2025
FMR LLC 4.1% $146,139,596 2,885,853 FMR LLC 31 Dec 2025
Sofinnova Venture Partners X, L.P. 4% $128,465,927 2,847,837 Dr. Maha Katabi ("Katabi") 10 Dec 2025
Point72 Asset Management, L.P. 1.7% $51,344,964 1,229,525 Point72 Asset Management, L.P. 25 Mar 2026

As of 31 Mar 2026, 227 institutional investors reported holding 72,234,409 shares of Vera Therapeutics, Inc. - Class A Common Stock, par value $0.001 per share (VERA). This represents 100% of the company’s total 72,325,000 outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
77%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Avoro Capital Advisors LLC 8.1% 5,888,888 0% 2.3% $236,909,964
BlackRock, Inc. 7% 5,088,102 +5.4% 0% $204,694,345
PRICE T ROWE ASSOCIATES INC /MD/ 6.3% 4,574,030 -16% 0.02% $184,014,000
Deep Track Capital, LP 5.7% 4,106,067 +46% 3.4% $165,187,075
DEERFIELD MANAGEMENT COMPANY, L.P. 5.1% 3,722,100 -8.3% 1.8% $149,740,083
Kynam Capital Management, LP 4.7% 3,398,224 -1% 8.7% $136,710,552
STATE STREET CORP 4.7% 3,363,638 +26% 0% $135,319,157
Sofinnova Investments, Inc. 3.9% 2,793,987 0% 5.6% $112,402,097
VANGUARD CAPITAL MANAGEMENT LLC 3.7% 2,683,607 0% 0% $107,961,510
FMR LLC 3.7% 2,676,422 -7.3% 0.01% $107,672,471
Eversept Partners, LP 3% 2,173,286 -29% 5.8% $87,431,296
Bellevue Group AG 2.4% 1,710,771 +0.74% 1.6% $68,824,317
Integral Health Asset Management, LLC 2.2% 1,600,000 -11% 3.4% $64,368,000
GEODE CAPITAL MANAGEMENT, LLC 2.2% 1,570,077 +8.7% 0% $63,177,383
Vestal Point Capital, LP 1.9% 1,368,159 +149% 1.5% $55,041,037
ALLIANCEBERNSTEIN L.P. 1.8% 1,314,242 +7.8% 0.02% $66,553,215
Point72 Asset Management, L.P. 1.7% 1,210,725 -30% 0.08% $48,707,467
GOLDMAN SACHS GROUP INC 1.6% 1,133,969 +1.2% 0.01% $45,619,573
Pictet Asset Management Holding SA 1.5% 1,051,583 -24% 0.04% $42,305,184
Woodline Partners LP 1.4% 1,001,037 +0.08% 0.15% $40,271,719
AMERICAN CENTURY COMPANIES INC 1% 728,330 -0.6% 0.02% $29,300,796
BANK OF AMERICA CORP /DE/ 0.82% 589,684 -15% 0% $23,722,987
VANGUARD PORTFOLIO MANAGEMENT LLC 0.76% 552,971 0% 0% $22,246,023
FRONTIER CAPITAL MANAGEMENT CO LLC 0.76% 551,493 +49% 0.23% $22,186,563
Qube Research & Technologies Ltd 0.75% 541,799 +43% 0.03% $21,796,574

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
20
Latest
Q1 2026
Rows shown
1-20 of 20
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 72,234,409 $2,918,504,853 -$101,315,946 $40.23 227
2025 Q4 74,007,592 $3,747,901,676 +$504,714,925 $50.64 214
2025 Q3 65,067,827 $1,890,768,857 +$37,111,876 $29.06 173
2025 Q2 63,893,006 $1,505,324,602 +$17,298,219 $23.56 171
2025 Q1 62,915,975 $1,512,522,250 -$90,036,678 $24.02 176
2024 Q4 62,912,622 $2,660,465,176 +$389,856,746 $42.29 177
2024 Q3 53,519,938 $2,365,061,400 -$1,769,076 $44.20 172
2024 Q2 52,988,211 $1,917,110,562 +$57,678,654 $36.18 169
2024 Q1 51,298,718 $2,212,007,022 +$474,171,827 $43.12 157
2023 Q4 41,345,437 $635,880,813 +$44,778,975 $15.38 93
2023 Q3 39,258,779 $538,195,352 +$9,620,413 $13.71 84
2023 Q2 38,127,621 $611,912,465 +$42,587,635 $16.05 76
2023 Q1 37,354,429 $289,749,836 +$137,641,985 $7.76 69
2022 Q4 21,331,464 $412,748,829 -$7,253,468 $19.35 57
2022 Q3 21,539,667 $459,015,997 +$19,117,341 $21.31 55
2022 Q2 20,391,008 $277,615,038 +$7,846,841 $13.61 49
2022 Q1 19,483,745 $457,319,068 +$130,146,246 $23.49 49
2021 Q4 14,054,730 $374,899,000 +$10,499,638 $26.72 37
2021 Q3 14,710,587 $252,433,000 +$4,174,540 $17.35 30
2021 Q2 14,513,290 $186,104,000 +$186,104,000 $13.25 21
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .